We demonstrated the excellent sensitivity and specificity of serum IGFBP7 and CSF IGFBP7 for the diagnosis of MS and NMOSD, as well as the outstanding quality of IGFBP7 and serum LAMP2 in forecasting the developing phenotypes of MS. Here, LAMP2 is linked to myeloid sarcoma.